Kollodis Inks Distribution Agreement With Cambridge Bioscience

Kollodis BioSciences (Kollodis) has entered into an exclusive distribution agreement with Cambridge Bioscience for the distribution of its MAPTrix ECM line of products for cell culture and related applications. It provides Cambridge Bioscience with the rights to distribute Kollodis’ cell culture products in the UK and Republic of Ireland.

The company said that among Mussel Adhesive Protein based matrix (MAPTrix) ECM line of products are reagents with genetically incorporated bioactive peptides (recognition peptides) that mimic the extracellular matrix (ECM) activity of collagen, fibronectin, laminin, and vitronectin proteins.

The bioactive peptide mimics the extracellular matrix (ECM) protein and provides for cell attachment, spreading and growth. The mussel adhesive protein confers biocompatible adhesion to a wide variety of surfaces.

A MAPTrix surface coating application promotes cell plating efficiency, improves morphology, and enhances cell proliferation under serum-free conditions in primary cell cultures such as hepatocytes or neural cells.

Mike Kerins, managing director at Cambridge Bioscience, said: “We are delighted to be working with Kollodis on the commercialisation of their highly innovative MAPTrix technology. We see wide application for this technology in the areas of stem cell research and tissue engineering.”